Ind Swift Laboratories
93.18
-1.57(-1.66%)
Market Cap₹- Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D-1.66%
1M-8.30%
6M-1.09%
1Y-6.01%
5Y+42.70%
View Company Insightsright
More news about Ind Swift Laboratories
11Aug 25
Ind Swift Laboratories Reports Strong Profit Growth and Completes Merger with Ind Swift Limited
Ind Swift Laboratories Limited (ISLL) announced robust financial results following its merger with Ind Swift Limited. The company reported a standalone net profit of Rs. 256.09 crores and revenue from operations of Rs. 549.65 crores. The merger, approved by NCLT, became effective on August 8. ISLL allotted 14.20 lakh preference shares to former Ind Swift Limited shareholders and converted 15.32 lakh equity warrants. Strategic asset sales and exceptional items contributed Rs. 223.20 crores to profits. The company's standalone EPS stood at Rs. 38.08.
31Jul 25
Ind-Swift Laboratories Merger with Ind-Swift Limited Gets NCLT Approval, Effective August 8, 2025
The National Company Law Tribunal (NCLT) has approved the merger of Ind-Swift Limited with Ind-Swift Laboratories Limited (ISLL). The amalgamation will be effective from August 8, 2025, with March 31, 2024, as the appointed date. The record date for determining eligible shareholders is set for August 14, 2025. Post-merger, ISLL's authorized share capital will increase to Rs. 140.00 crores, comprising 11.50 crore equity shares and 25.00 lakh preference shares. Ind-Swift Limited will be dissolved without winding up. The merger is expected to create operational synergies and potentially strengthen the market position of the combined entity.
28Jul 25
Ind-Swift Laboratories Secures NCLT Approval for Merger with Ind-Swift Limited
Ind Swift Laboratories Limited (ISLL) has obtained final approval from the National Company Law Tribunal (NCLT) for its merger with Ind-Swift Limited. The NCLT Chandigarh Bench approved the amalgamation scheme, which will affect shareholders and creditors of both companies. ISLL has made the NCLT order publicly available on its website for transparency. The merger is expected to streamline operations and create potential synergies between the two entities.
18Jun 25
Ind-Swift Laboratories Invests ₹950 Million in Khandelwal Finance's OCRPS
Ind-Swift Laboratories has approved an investment of ₹950.00 million in Khandelwal Finance through Optionally Convertible Redeemable Preference Shares (OCRPS). This strategic move represents a significant financial decision for the pharmaceutical company, potentially diversifying its investment portfolio and providing opportunities for future equity conversion or steady income through fixed dividends.
28Mar 25
Ind-Swift Laboratories Approves Rs 20 Crore Short-Term Advance to Ashok Investors Trust
Ind-Swift Laboratories Ltd (ISLL) has approved a short-term advance of up to Rs 20 crore to Ashok Investors Trust Limited (AITL), a registered NBFC. The advance is in the form of an Inter-Corporate Deposit with a 30-day term, extendable for another 30 days, at 10% annual interest. The transaction is secured by post-dated cheques and is not a related party transaction. ISLL already holds 800 NCDs of AITL, each with a face value of Rs 5,00,000.
Ind Swift Laboratories
93.18
-1.57
(-1.66%)
1 Year Returns:-6.01%
Industry Peers
Windlas Biotech
790.15
(+0.55%)
Jeena Sikho Lifecare
699.20
(+0.52%)
Blue Jet Healthcare
554.80
(-2.56%)
Abbott
28,850.00
(-0.14%)
Sunrest Lifescience
42.05
(-2.21%)
Zenith Drugs
54.60
(+2.25%)
Pfizer
5,001.00
(+0.57%)
FDC
414.10
(+0.24%)